George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
https://*********************/companies/uk/medical-equipment-services/physiomics-plc/research/hybridan/strongest-ever-pipeline-as-proprietary-personalised-medcine-tool-for-prostate-cancer-heads-to-the-cl/a0eaf928-af8e-4567-8cb1-529d68fb764a
Strongest ever pipeline as proprietary personalised medcine tool for prostate cancer heads to the clinic
Expected revenue about 9ook.
What will get sp moving is if we have positive news about personalised medicine, more upcoming new contracts, renewing contract with Merck again.
Hope it will be a good day tomorrow.
Again, that last trade was at 14:06 for 8.36 was a sell, the bid at that time was 8.3 and offer was 8.8, but it’s showing up as a buy.
The last 3 large deals were in fact sells, if you check time of execution they were close to bid price. Which makes the amount of sells and buys just about equal so far.
Would have thought the company had decided on the new Biosimulation Scientist they would employ and inform us, also results due end of month.
Are company going to have different classifications for VT.
VT9 for dual immuno- oncology.
VT? For personalised medicine.
VT? Other oncology.
Who knows.
The abstract on mentions VT9?
https://scholar.google.co.uk/citations?user=maDv-ycAAAAJ&hl=en#d=gs_md_cita-d&u=%2Fcitations%3Fview_op%3Dview_citation%26hl%3Den%26user%3DmaDv-ycAAAAJ%26cstart%3D20%26pagesize%3D80%26citation_for_view%3DmaDv-ycAAAAJ%3AM3NEmzRMIkIC%26tzom%3D-60
Abstract LB-392: Optimizing dual immuno-oncology combinations with a virtual tumor
Authors
Fernando Ortega, Frances A Brightman, Christophe Chassagnole
Publication date
2020/8/15
Source
Cancer Research
Volume
80
Issue
16 Supplement
Pages
LB-392-LB-392
Publisher
American Association for Cancer Research
Description
The purpose of the study was to investigate the application of a ‘virtual tumor9 (‘VT9) technology to optimizing the dosing and scheduling of dual immuno-oncology combinations in order to maximize the immunopotentiation and anti-tumor efficacy
From Cancer Research published 15/08/2020, (maybe the same or could be updated from their poster for AACR June 2020).
Abstract LB-392: Optimizing dual immuno-oncology combinations with a virtual tumor.
https://cancerres.aacrjournals.org/content/80/16_Supplement/LB-392.abstract
Check date and time, it was a buy yesterday.
https://twitter.com/Physiomics?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Not a massive buy but late on Friday evening there were 300,000 bought on prtdf.
Net sales predictions up for 2021.
https://www.marketscreener.com/PHYSIOMICS-PLC-32526450/financials/
It was a sell from yesterday, buys were above 4.7 at that time, sells were 4.65 or less.
Date Time Trade Prc Volume Buy/Sell Value
11-Jun-20 15:54:43 4.60 526,000 Sell* 24.20k
Simply Wall St
Companies Like Physiomics (LON:PYC) Are In A Position To Invest In Growth
https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-pyc/physiomics-shares/news/companies-like-physiomics-lonpyc-are-in-a-position-to-invest-in-growth/&ved=2ahUKEwjSjJmFl_7oAhXBiVwKHf4KC24QxfQBMAV6BAgFEAQ&usg=AOvVaw0xxCyOhTC74iZTV5DEcZyC
All quiet from poster physiomics/Vtai
https://www.physiomics.co.uk/the-virtual-tumour-part-iii-model-error-versus-initial-condition-error/
Not the company but poster.
Physiomics has changed name now to VTAI (virtual tumour artificial intelligence) I presume.
Forecast for 2020 up to £900k, with debt decreasing.
https://www.marketscreener.com/PHYSIOMICS-PLC-32526450/financials/
Ccs1477 in trials.
https://www.cellcentric.com/updates/
Bicycle therapeutics update for bt1718.
https://www.bioportfolio.com/news/article/4097557/Bicycle-Therapeutics-Announces-Presentation-of-Updated-Data-from-Phase-I-IIa-Trial.html